about
Interventions for sexual dysfunction following treatments for cancerThe phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporterEfficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study.Identification of a new analogue of sildenafil added illegally to a functional food marketed for penile erectile dysfunction.The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction.JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation
P2860
Q24242883-DA5CD2BC-930A-4666-BF4E-821C44DC06FDQ28477938-0EE863D5-B7B6-4AD2-AA1D-02BF7D7C5BE1Q34139231-CBE1EFBB-D513-4D90-9AD6-8E4EAE5E6598Q34234259-D0CB1F0A-93FB-4DE7-AE3B-70EF1CDB41AAQ36229351-8AA78566-0E09-450C-A4E5-9ED587FC400DQ36599937-A203C325-5D0E-481A-A06E-C9D4E43A38AEQ42325938-6A5E3F87-2CBF-4F89-A0DE-8D9B34FDDC9BQ44362851-FA60C2A7-325B-423A-AD05-843187ADAF68Q46983898-4B993DE4-DE17-4D17-927F-F1BCB7979E54Q56781955-1304325E-8868-4293-BDAF-1C0F6A89F1E4
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Vardenafil.
@ast
Vardenafil.
@en
Vardenafil.
@nl
type
label
Vardenafil.
@ast
Vardenafil.
@en
Vardenafil.
@nl
prefLabel
Vardenafil.
@ast
Vardenafil.
@en
Vardenafil.
@nl
P1433
P1476
Vardenafil.
@en
P2093
Douglas Ormrod
Stephanie E Easthope
P304
217-27; discussion 228-9
P356
10.2165/00002512-200219030-00005
P577
2002-01-01T00:00:00Z
P6179
1043402776